FIELD: biotechnology; medicine.
SUBSTANCE: present invention relates to biotechnology and can be used in medicine. There are disclosed new compounds capable of inhibiting serine proteases 1 and 2 (MASP1 and MASP2) associated with mannose binding lectin (MBL).
EFFECT: invention is applicable for prevention or treatment of various renal pathologies, particularly in acute renal failure.
9 cl, 22 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AND DRUG CONJUGATES (ADC) AND ANTIBODY AND PRODRUG CONJUGATES (APDC) CONTAINING ENZYMATICALLY CLEAVABLE GROUPS | 2016 |
|
RU2751512C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| METHODS FOR PRODUCING OXYTOCIN ANALOGUES | 2015 |
|
RU2696276C2 |
| PEPTIDE VECTORS | 2004 |
|
RU2361876C2 |
| OXYTOCIN RECEPTOR AGONISTS | 2010 |
|
RU2539692C2 |
| NOVEL ANALOGUES OF GLUCAGON-LIKE PEPTIDE, COMPOSITION AND METHOD OF USE | 2010 |
|
RU2557301C2 |
| GLP-1 PEPTIDE HAVING ATTACHED OLIGOSACCHARIDE CHAIN | 2008 |
|
RU2539829C2 |
| METHOD FOR PRODUCING PEPTIDE EXENATIDE | 2011 |
|
RU2458066C1 |
| METHOD FOR CLEAVAGE OF SOLID PHASE-BOUND PEPTIDES FROM THE SOLID PHASE | 2019 |
|
RU2771712C2 |
| SYNTHESIS OF LIXISENATIDE WITH CAPPING | 2019 |
|
RU2782772C2 |
